An open-label, parallel, multiple-dose study comparing the pharmacokinetics and gastric acid suppression of rabeprazole extended-release with esomeprazole 40 mg and rabeprazole delayed-release 20 mg in healthy volunteers.

Abstract

BACKGROUND Novel rabeprazole extended-release (ER) formulations were developed to provide prolonged gastric acid suppression and potentially improved clinical outcomes in GERD patients. AIM To evaluate the pharmacodynamics and pharmacokinetics of six rabeprazole-ER formulations vs. esomeprazole 40 mg and rabeprazole delayed-release (DR) 20 mg. METHODS… (More)
DOI: 10.1111/j.1365-2036.2011.04580.x

Topics

Cite this paper

@article{Morelli2011AnOP, title={An open-label, parallel, multiple-dose study comparing the pharmacokinetics and gastric acid suppression of rabeprazole extended-release with esomeprazole 40 mg and rabeprazole delayed-release 20 mg in healthy volunteers.}, author={Gilda Morelli and Howard Chen and Guillermo Rossiter and Bhaskar Rege and Y. Lu}, journal={Alimentary pharmacology & therapeutics}, year={2011}, volume={33 7}, pages={845-54} }